Can pemetinib significantly extend life? What are the patient survival data?

Pemigatinib is a selective FGFR (fibroblast growth factor receptor) inhibitor, mainly used to treat patients with advanced or metastatic cholangiocarcinoma (CCA) carrying FGFR2 fusion or rearrangement mutations. As a targeted drug, it can effectively inhibit the FGFR signaling pathway, thereby preventing the growth and spread of tumor cells. Clinical studies have shown that pemetinib has certain therapeutic advantages for patients with cholangiocarcinoma with specific gene mutations, but its impact on survival varies depending on individual circumstances.

In a pivotal clinical trial (FIGHT-202 study), pemetinib was used to treat patients with cholangiocarcinoma who had failed at least one prior systemic therapy, data showed that ORR) of patients with n>FGFR2fusion or rearrangement mutations is 35.5%, and some patients can achieve complete response or partial response. In addition, the study's median progression-free survival (PFS) was 6.9 months, and the median overall survival ( pan>OS) was 21.1 months. Compared with traditional chemotherapy regimens, pemetinib has a more significant survival benefit in specific groups of people. However, for patients with cholangiocarcinoma who do not carry FGFR2 mutations, the efficacy of pemetinib is lower, so its scope of application is more limited.

Although pemetinib has shown some advantages in extending survival, it is not the best option for all patients. Some patients may experience a decrease in therapeutic effect due to drug resistance or disease progression. Especially after using pemetinib for a period of time, other mutations or bypass activation mechanisms may occur in the FGFR2 pathway, which may affect drug efficacy. Therefore, for patients treated with pemetinib, doctors usually closely monitor disease progression and adjust the treatment plan if necessary, such as combining other treatments or changing targeted drugs.

Overall, pemetinib can significantly prolong survival and provide higher response rates in patients with cholangiocarcinoma harboring FGFR2 fusion or rearrangement mutations. However, its specific efficacy varies between individuals, and some patients may need to adjust treatment strategies due to drug resistance or side effects. In the future, through combination therapy or more precise molecular screening, pemetinib may bring longer survival and better quality of life to more patients with cholangiocarcinoma.

Reference materials:https://go.drugbank.com/drugs/DB15102